<DOC>
	<DOC>NCT00036543</DOC>
	<brief_summary>This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.</brief_summary>
	<brief_title>A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Diagnosis of prostate cancer. Rising PSA while on hormonal therapy or following surgical castration. Documented evidence of metastatic disease. Have received cytotoxic chemotherapy. Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Hormone-Refractory, Prostate Cancer</keyword>
</DOC>